InvestmentUpdated on 21 November 2023
A biomolecule for treating life threatening women's health conditions
About
-
Branson Pharma develop a bio molecule that demonstrates a high efficacy and speed to eliminate a range of infections related to gynecologic conditions in uterus and fallopian tubes (endometritis, endometriosis, adenomyosis, etc.)
-
The molecule specifically targets infected cells only, dissolving dead and infected tissue by breaking any infection down into basic amino acids and removing them
-
Early tests demonstrated a significant efficacy closer to 100% treatment rate
-
At Branson Pharma we believe the final product can be called a cure
-
Cost effective to produce
-
We are now open to discuss co-investment options and to decide on locating future manufacuring in the EU
Stage
- Seed and Development
- Startup
Applies to
- Biotech, Pharma and Cosmetics
- Healthcare
Organisation
Baar, Switzerland
Similar opportunities
Service
- Development
- Biotech and Lifescience
Daniel Soric
Founder at Deep LS j.d.o.o.
Okrug Gornji, Croatia
Partnership
- Coaching
- Consulting
- Development
- Manufacturing
Željka Barišić
Business Development Manager at Jeltom d.o.o.
Zagreb, Croatia
Investment
- Energy
- Startup
- Maturity
- Expansion
- Electronics
- Environment
- Possible Exit
- Seed and Development
- Growth and Establishment
Željka Barišić
Business Development Manager at Jeltom d.o.o.
Zagreb, Croatia